Trying to work out whether the combination is doing something a higher single-agent dose would not, or whether it is a more expensive way to reach the same place.
What I am after is whether the amylin component adds anything beyond what a higher GLP-1 dose would achieve.
Numbers rather than impressions, if you have them.
Taking the question as asked, rather than the general version of it. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.
LarryQC_SD said:Relative and absolute effects need reading together.
Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultstommy_boulder said:Trying to work out whether the combination is doing something a higher single-agent dose would not, or whether it is a more expensive way to reach the…
Adding a me-too, because a thread of one person's experience is not much use.
From the other side of the consultation, briefly. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.
Ask again with the specifics and you will get a better answer than this one.